8-K

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM8-K

CURRENTREPORT

PURSUANTTO SECTION 13 OR 15(D) OF THE

SECURITIESEXCHANGE ACT OF 1934

Dateof Report (Date of earliest event reported): August 14, 2020

INTERPACEBiosciences, INC.

(Exactname of Registrant as specified in its charter)

MorrisCorporate Center 1, Building C

300Interpace Parkway,

Parsippany,NJ 07054

(Address, including zip code, of Principal Executive Offices)

(855)776-6419

Registrant’s telephone number, including area code:

NotApplicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securitiesregistered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

[  ] Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

Item8.01 Other Events.

Interpace Biosciences, Inc. (the “Company”) expects to file a Notification of Late Filing on Form 12b-25 disclosing that the Company is unable to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 (the “Form 10-Q”) within the prescribed time period. In July 2020, the Company received letters from several employees, one of whom has left the Company’s employ, concerning certain employment and billing and compliance matters. In response, the Company informed its Audit Committee and Regulatory Compliance Committee as well as its independent registered public accounting firm. The Audit Committee commenced an investigation of these matters with the assistance of independent counsel and an advisor thereto. Currently, the investigation is still in process and is unable to be completed by the filing deadline for the Form 10-Q.

In addition, the Company expects that when the Form 10-Q is filed that it will not be in compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirements.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 14, 2020